Differential Effects of Raloxifene and Estrogen on Insulin Sensitivity in Postmenopausal Women
Authors:
- 29 April 2003
- journal article
- clinical trial
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 51 (5) , 683-688
Abstract
OBJECTIVES: To test the hypothesis that both raloxifene and estrogen would improve insulin sensitivity in postmenopausal women and that the magnitude of the effect would be similar for both drugs. DESIGN: Placebo‐controlled, double‐blind, randomized study. SETTING: The General Clinical Research Center of the University of Michigan Medical Center, a university hospital. PARTICIPANTS: Forty‐four healthy postmenopausal women 73 ± 7 years old (mean age ± standard deviation) who were not receiving hormone replacement therapy. INTERVENTION: Eight weeks of drug therapy with randomization to raloxifene (n = 16), estrogen (n = 14), or placebo (n = 14). MEASUREMENTS: These subjects underwent a frequently sampled intravenous glucose tolerance test to determine insulin sensitivity (S I ) and total and regional (central) body composition measurements by dual‐energy x‐ray absorptiometry at baseline and after 8 weeks of drug therapy. RESULTS: There were no statistically significant differences in age, body mass index, total or central fat mass, or S I between the three groups at baseline. The major outcome variable was S I . After 8 weeks of drug therapy, there was no significant change in S I in the placebo group or in the estrogen group and a significant decrease in S I in the raloxifene group, P = .003. CONCLUSION: In contrast to estrogen's ability to maintain insulin sensitivity, raloxifene decreases insulin sensitivity in healthy nondiabetic postmenopausal women. The clinical significance of this effect of raloxifene to impair insulin sensitivity in postmenopausal women warrants further evaluation in future studies.Keywords
This publication has 38 references indexed in Scilit:
- Raloxifene Does Not Affect Insulin Sensitivity or Glycemic Control in Postmenopausal Women with Type 2 Diabetes Mellitus: A Randomized Clinical TrialThe Journal of Clinical Endocrinology & Metabolism, 2002
- Effects of the Selective Estrogen Receptor Modulator, Raloxifene, on the Somatotropic Axis and Insulin-Glucose HomeostasisThe Journal of Clinical Endocrinology & Metabolism, 2001
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJAMA, 1998
- Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal WomenNew England Journal of Medicine, 1997
- Differential Ligand Activation of Estrogen Receptors ERα and ERβ at AP1 SitesScience, 1997
- Identification of an Estrogen Response Element Activated by Metabolites of 17β-Estradiol and RaloxifeneScience, 1996
- Decreased sex hormone-binding globulin predicts noninsulin-dependent diabetes mellitus in women but not in menThe Journal of Clinical Endocrinology & Metabolism, 1993
- Effects of low doses of transdermal 17 beta-estradiol on carbohydrate metabolism in postmenopausal womenThe Journal of Clinical Endocrinology & Metabolism, 1992
- Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp.Journal of Clinical Investigation, 1987
- Relative effects of pregnancy, estradiol, and progesterone on plasma insulin and pancreatic islet insulin secretionJournal of Clinical Investigation, 1971